National Asset Management Inc. grew its position in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) by 33.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,200 shares of the specialty pharmaceutical company’s stock after buying an additional 11,500 shares during the quarter. National Asset Management Inc. owned approximately 0.08% of Paratek Pharmaceuticals worth $138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also made changes to their positions in PRTK. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Paratek Pharmaceuticals during the 4th quarter valued at about $76,000. BNP Paribas Arbitrage SA lifted its holdings in Paratek Pharmaceuticals by 510.3% in the 4th quarter. BNP Paribas Arbitrage SA now owns 48,624 shares of the specialty pharmaceutical company’s stock worth $218,000 after purchasing an additional 40,657 shares during the last quarter. Gamco Investors INC. ET AL lifted its holdings in Paratek Pharmaceuticals by 44.1% in the 4th quarter. Gamco Investors INC. ET AL now owns 49,000 shares of the specialty pharmaceutical company’s stock worth $220,000 after purchasing an additional 15,000 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Paratek Pharmaceuticals in the 4th quarter worth approximately $1,064,000. Finally, CM Management LLC lifted its holdings in Paratek Pharmaceuticals by 50.0% in the 4th quarter. CM Management LLC now owns 300,000 shares of the specialty pharmaceutical company’s stock worth $1,347,000 after purchasing an additional 100,000 shares during the last quarter. 59.46% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
PRTK has been the subject of several analyst reports. BTIG Research reduced their target price on Paratek Pharmaceuticals from $34.00 to $30.00 in a report on Monday, April 11th. StockNews.com upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 5th. Finally, HC Wainwright dropped their price target on Paratek Pharmaceuticals from $22.00 to $20.00 in a research report on Friday, May 6th.
Paratek Pharmaceuticals Stock Down 1.7 %
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) last issued its quarterly earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). The business had revenue of $24.86 million during the quarter, compared to the consensus estimate of $27.15 million. During the same period in the prior year, the firm earned ($0.39) earnings per share. Sell-side analysts expect that Paratek Pharmaceuticals, Inc. will post -0.71 earnings per share for the current fiscal year.
Paratek Pharmaceuticals Profile
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.
- Get a free copy of the StockNews.com research report on Paratek Pharmaceuticals (PRTK)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- Deep Value High Yield Newell Brands Is Ready To Bottom
- The Colgate-Palmolive Growth Outlook Brightens
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.